The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor
Abstract
BACKGROUND.: Sunitinib malate is a novel multitargeted receptor tyrosine kinase inhibitor with established efficacy in the treatment of metastatic renal cell carcinoma and imatinib‐resistant gastrointestinal stromal tumor. This report describes the development of heart failure in cancer patients who received this novel agent. METHODS.: A retrospective study was conducted at M. D. Anderson Cancer Center during a 1‐year period on patients who received sunitinib and developed heart failure. RESULTS.: During 2006, 6 of 224 (2.7%) patients who received sunitinib developed heart failure (HF) that resulted in substantial morbidity and, in some cases, mortality. Symptomatic heart failure occurred soon after initiation of sunitinib (mean onset 22 days after initiation), was associated with decline in cardiac function and elevations in blood pressure, and was not completely reversible in most patients, even after termination of sunitinib therapy. CONCLUSIONS.: These observations suggested that sunitinib‐associated heart failure may represent a potentially serious toxicity and underscore the need for careful monitoring of cardiac function and aggressive control of hypertension in these patients. Studies to elucidate potential mechanisms of heart failure and left ventricular dysfunction resulting from treatment with sunitinib are necessary to develop strategies for prevention and treatment of this complication. Cancer 2008. ©2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy
Kadish, A., Dyer, A., Daubert, J. P., Quigg, R., Estes, N. A. M., Anderson, K. P., Calkins, H., Hoch, D., Goldberger, J., Shalaby, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033088 · Cited by 2,080
Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study
Lloyd-Jones, D. M., Larson, M. G., Leip, E. P., Beiser, A., D’Agostino, R. B., Kannel, W. B., Murabito, J. M., Vasan, R. S., Benjamin, E. J., & Levy, D. (2002) · Circulation · doi:10.1161/01.cir.0000039105.49749.6f · Cited by 1,613
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., Redman, B. G., Margolin, K. A., Merchan, J. R., Wilding, G., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2516 · Cited by 1,230
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Self-citationFiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 405
Hsieh, P. C. H. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25878 · Cited by 357 · cited 1×
“tion of PDGF prevents development of cardiac dysfunction after myocardial infarction, seemingly acting directly to protect cardiac myocytes from ischemic stress.(25) More generally, preclinical studies have demonstrated that intact receptor tyrosine kinase signaling within the heart is essential to preserve the”
BackgroundOrgan weight in 684 adult autopsies: new tables for a Caucasoid population
de la Grandmaison, G. L., Clairand, I., & Durigon, M. (2001) · Forensic Science International · doi:10.1016/s0379-0738(00)00401-1 · Cited by 346
Heart failure with a normal ejection fraction
Sanderson, J. E. (2007) · Heart · doi:10.1136/hrt.2005.074187 · Cited by 295
The Role of Hypertension in the Pathogenesis of Heart Failure: A Clinical Mechanistic Overview
Vasan, R. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440150033003 · Cited by 247
Atrial Fibrillation and Ventricular Dysfunction: A Vicious Electromechanical Cycle
Cha, Y.-M., Redfield, M. M., Shen, W.-K., & Gersh, B. J. (2004) · Circulation · doi:10.1161/01.cir.0000132470.78896.a8 · Cited by 247
Rock, E. P., Goodman, V., Jiang, J. X., Mahjoob, K., Verbois, S. L., Morse, D., Dagher, R., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-107 · Cited by 247
Bevacizumab: An Angiogenesis Inhibitor with Efficacy in Colorectal and Other Malignancies
Zondor, S. D., & Medina, P. J. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d470 · Cited by 135
Angiogenesis Inhibitors and Hypertension: An Emerging Issue
Sica, D. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5740 · Cited by 127
Sarzani, R., Arnaldi, G., & Chobanian, A. V. (1991) · Hypertension · doi:10.1161/01.hyp.17.6.888 · Cited by 64
Hypothyroid Cardiomyopathy: Echocardiographic Documentation of Reversibility
Shenoy, M. M., & Goldman, J. M. (1987) · The American Journal of the Medical Sciences · doi:10.1097/00000441-198707000-00001 · Cited by 33
Growth-promoting effect of platelet-derived growth factor on rat cardiac myocytes
Liu, J., Wu, L., Li, L., et al. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.10.018 · Cited by 22
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationRini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Self-citationCurigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.023 · Cited by 1,031
Self-citationCardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp440 · Cited by 839
Metadata
- Authors
- Khakoo, A. Y., Kassiotis, C. M., Tannir, N., Plana, J. C., Halushka, M., Bickford, C., Trent, J., Champion, J. C., Durand, J., & Lenihan, D. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-04-03
- Volume
- 112
- Issue
- 11
- Pages
- 2500-2508
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2116137381
- Cited by
- 252
- References
- 25
- FWCI
- 22.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.